| Primary | Aortic Vascular Inflammation as Measured by FDG-PET/CT | Change from baseline in the target to background ratio from the whole aorta. Effect of secukinumab 300 mg subcutaneous (sc) compared to placebo on aortic vascular inflammation with respect to the change from baseline in the target (arterial vascular uptake) to background (venous blood pool) ratio from the aorta. The primary analysis time point was at Week 12. Increased aortic vascular inflammation as measured by (18F) fluorodeoxyglucose positron emission tomography with computer assisted tomography (FDG-PET/CT) | Full Analysis Set (FAS) included all participants assigned medication. Patients inappropriately randomized (eg, IRT was called in error for randomization of a screen failed patient) were excluded from this analysis set. Following intent-to-treat principle, participants were analyzed according to treatment they were assigned to at randomization | Posted | | Mean | Standard Deviation | target to background ratio (TBR) | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| | | Title | Denominators | Categories |
|---|
| Baseline | - ParticipantsOG00043
- ParticipantsOG00142
| |
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| Statistical analysis (Analysis of Covariance) of change from baseline in target to background ratio for regions of the aorta at Week 12 (Full Analysis Set) | ANCOVA | | 0.3712 | | Least Square Mean | -0.053 | Standard Error of the Mean | 0.059 | 2-Sided | 95 | -0.169 | 0.064 | | | | | Superiority | This superiority trial compares secukinumab with placebo with a view of demonstrating the superiority of secukinumab over placebo with regards to a specific outcome measure. | |
|
| Secondary | Change in Adiponectin Total | Change from baseline in Adiponectin to measure adiposity | | Posted | | Mean | Standard Deviation | ng/mL | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Change in Apolipoprotein B | Change from baseline in Apolipoprotein B levels, a marker predictive of diabetes | | Posted | | Mean | Standard Deviation | ng/mL | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Change in CRP | Change from baseline in C reactive protein (CRP), a measure of inflammation | | Posted | | Mean | Standard Deviation | mg/L | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Change in Cholesterol | Change from baseline in Cholesterol level | | Posted | | Mean | Standard Deviation | mg/dL | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Change in Fetuin A | Change from baseline in Fetuin A, a marker predictive of diabetes | | Posted | | Mean | Standard Deviation | ng/mL | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Change in Ferritin | Change from baseline in Ferritin, a marker predictive of diabetes | | Posted | | Mean | Standard Deviation | ng/mL | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Change in GlycA | Change from baseline in glycoprotein acetylation (GlycA), a marker of inflammation | | Posted | | Mean | Standard Deviation | μmol/L | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Change in HDL Cholesterol | Change from baseline in High Density Lipoprotein (HDL) Cholesterol, a cardiometabolic biomarker | | Posted | | Mean | Standard Deviation | mg/dL | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Change in HDL Function (Cholesterol Efflux) | Change from baseline in High Density Lipoprotein (HDL) Cholesterol (cholesterol efflux) , a cardiometabolic biomarker Ratio of the pleated serum to removal of Cholesterol | | Posted | | Mean | Standard Deviation | ratio | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | HDL Particle Total | Change from baseline in High Density Lipoprotein (HDL) Cholesterol Particle Total | | Posted | | Mean | Standard Deviation | μmol/L | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | HDL Size | Change from baseline in High Density Lipoprotein (HDL) Cholesterol size | | Posted | | Mean | Standard Deviation | nm | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | HOMA-IR | Homeostatic Model Assessment-Insulin Resistance (HOMA-IR) Insulin [uIU/mL (mU/L)] x Glucose (mg/dL) = HOMA-IR | | Posted | | Mean | Standard Deviation | HOMA-IR units | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Change in IL-2 Receptor A | Interleukin-2 Receptor A (IL-2RA) is a marker predictive of diabetes | | Posted | | Mean | Standard Deviation | pg/mL | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Change in IL-18 | Interleukin-18 (IL-18) is a marker predictive of diabetes | | Posted | | Mean | Standard Deviation | pg/mL | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Change in IL-6 | Interleukin 6 (IL-6) is a marker of inflammation | | Posted | | Mean | Standard Deviation | pg/mL | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Change in Intermediate-Density Lipoprotein (IDL) Particle | Intermediate-density lipoprotein (IDL) particle is a marker of cardiometabolic function | | Posted | | Mean | Standard Deviation | nmol/mL | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Change LDL Cholesterol | Change from baseline in Low-Density Lipoprotein (LDL) Cholesterol as a marker of cardiometabolic function | | Posted | | Mean | Standard Deviation | mg/dL | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Change in Leptin | Change from baseline in Leptin a marker of adiposity | | Posted | | Mean | Standard Deviation | pg/mL | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | LDL Particle Total | Change from baseline in Low Density Lipoprotein (LDL) Cholesterol Particle Total | | Posted | | Mean | Standard Deviation | nmol/L | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | LDL Size | Change from baseline in Low Density Lipoprotein (LDL) Cholesterol size | | Posted | | Mean | Standard Deviation | nm | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Change in Triglycerides | Triglycerides are a marker of cardiometabolic function | | Posted | | Mean | Standard Deviation | mg/dL | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Change in TNF-α | Change in Tumor necrosis factor (TNF, tumor necrosis factor alpha, TNFα is a marker of inflammation Also written as TNF-alpha | | Posted | | Mean | Standard Deviation | pg/mL | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Change VLDL Particle Total | Change in Very-low-density lipoprotein (VLDL) cholesterol level | | Posted | | Mean | Standard Deviation | nmol/L | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | VLDL Size | Change from baseline in Very Low Density Lipoprotein (VLDL) Cholesterol size | | Posted | | Mean | Standard Deviation | nm | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Area and Severity Index 75 (PASI 75) | Percentage of participants with PASI75 response (yes, no) PASI75 response = at least a 75% improvement (reduction) in PASI score compared to baseline Psoriasis Area and Severity Index ( PASI) is a tool for measuring the severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease). | | Posted | | Number | | percentage of participants | | week 12 | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Psoriasis Area and Severity Index 90 (PASI 90) | Percentage of participants with PASI90 response (yes, no) PASI90 response = at least a 90& improvement (reduction) in PASI score compared to baseline | | Posted | | Number | | percentage of participants | | week 12 | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Psoriasis Area and Severity Index 100 (PASI100) | Percentage of participants with PASI100 response (yes, no) PASI100 response = complete clearing of psoriasis | | Posted | | Number | | percentage of participants | | week 12 | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Investigator's Global Assessment Modified 2011 (IGA Mod 2011) Score of 0 or 1 | percentage of participants with IGA mod 2011 score of 0 or 1 (yes, no) Investigator's Global Assessment modified 2011 (IGA mod 2011) score of 0 or 1 Statistical analysis (Cochran-Mantel-Haenszel test) of Novartis Investigator's Global Assessment Modified 2011 0 or 1 response by visit (Non-responder Imputation) | | Posted | | Number | | percentage of participants | | week 12 | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |
| Secondary | Dermatology Life Quality Index (DLQI) Total Score | Change from baseline in the DLQI total score Summary of analysis of change from baseline in DLQI at Week 12 and statistical analysis (using Analysis of Covariance) of change from baseline in DLQI at Week 12 The higher the score, the more quality of life is impaired. 0 - 1 no effect at all on patient's life 2 - 5 small effect on patient's life 6 - 10 moderate effect on patient's life 11 - 20 very large effect on patient's life 21 - 30 extremely large effect on patient's life | | Posted | | Mean | Standard Deviation | scores on a scale | | baseline, 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Secukinumab | Eligible participants received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by monthly dosing starting at Week 8 through Week 48 | | OG001 | Placebo | Eligible participants received placebo once weekly at Baseline, Weeks 1, 2, 3, and 4 followed by a dose after four weeks at Week 8; participants were switched to once weekly secukinumab 300 mg at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing through Week 48 |
| |